Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
Leotta S, Markovic U, Duminuco A, Mulè A, Porretto F, Federico V, Gentile M, Pastore D, Nigro LL, Selleri C, Serio B, Calafiore V, Patti C, Mauro E, Vetro C, Maugeri C, Parisi M, Fiumara P, Parrinello L, Marino S, Scuderi G, Garibaldi B, Musso M, Renzo ND, Vigna E, Martino EA, Raimondo FD, Milone G. Leotta S, et al. Among authors: patti c. Ann Hematol. 2024 Apr 13. doi: 10.1007/s00277-024-05725-9. Online ahead of print. Ann Hematol. 2024. PMID: 38609726
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Mauro FR, Scalzulli PR, Scarfò L, Minoia C, Murru R, Sportoletti P, Frigeri F, Albano F, Di Renzo N, Sanna A, Laurenti L, Massaia M, Cassin R, Coscia M, Patti C, Pennese E, Tafuri A, Chiarenza A, Galieni P, Perbellini O, Selleri C, Califano C, Ferrara F, Cuneo A, Murineddu M, Palumbo G, Scortechini I, Tedeschi A, Trentin L, Varettoni M, Pane F, Liberati AM, Merli F, Morello L, Musuraca G, Tani M, Ibatici A, Regazzoni G, Di Candia M, Palma M, Arienti D, Molica S. Mauro FR, et al. Among authors: patti c. Cancers (Basel). 2024 Mar 20;16(6):1228. doi: 10.3390/cancers16061228. Cancers (Basel). 2024. PMID: 38539561 Free PMC article.
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, Carras S, Gini G, Camus V, Mancuso S, Marcheselli L, Ferrari A, Merli M, Tessoulin B, Stelitano C, Beldjord K, Roti G, Jardin F, Castagnari B, Palombi F, Baseggio L, Traverse-Glehen A, Tripodo C, Liberati AM, Parolini M, Usai S, Patti C, Federico M, Musso M, Ladetto M, Zucca E, Thieblemont C. Iannitto E, et al. Among authors: patti c. Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109. Online ahead of print. Haematologica. 2024. PMID: 38497158 Free article.
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies.
Viviani S, Vanazzi A, Frassoni S, Rusconi C, Rossi A, Romano A, Patti C, Schiavotto C, Sorasio R, Marasco V, Lissandrini L, Rapezzi D, Gottardi D, Cocito F, Mulè A, Leotta S, Gini G, Sorio M, Derenzini E, Rambaldi A, Bagnardi V, Tarella C. Viviani S, et al. Among authors: patti c. Leuk Lymphoma. 2024 Apr;65(4):460-471. doi: 10.1080/10428194.2023.2298273. Epub 2024 Jan 2. Leuk Lymphoma. 2024. PMID: 38164812
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).
Phillips TJ, Avigdor A, Gurion R, Patti C, Corradini P, Tani M, Mehta A, Lossos IS, Zinzani PL, Thieblemont C, Jurczak W, Zheng F, Rappold E, Zhao W, Jiang P, Johnson P. Phillips TJ, et al. Among authors: patti c. Blood Adv. 2024 Feb 27;8(4):867-877. doi: 10.1182/bloodadvances.2023010648. Blood Adv. 2024. PMID: 38113459 Free PMC article. Clinical Trial.
Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. J. Clin. Med. 2022, 11, 7162.
Bocci G, Pelliccia S, Orlandi P, Caridi M, Banchi M, Musuraca G, Di Napoli A, Bianchi MP, Patti C, Anticoli-Borza P, Battistini R, Casaroli I, Lanzolla T, Tafuri A, Cox MC. Bocci G, et al. Among authors: patti c. J Clin Med. 2023 Nov 13;12(22):7053. doi: 10.3390/jcm12227053. J Clin Med. 2023. PMID: 38002810 Free PMC article.
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial.
Ladetto M, Tavarozzi R, Zanni M, Evangelista A, Ferrero S, Tucci A, Botto B, Bolis S, Volpetti S, Zilioli VR, Puccini B, Arcari A, Pavone V, Gaidano G, Corradini P, Tani M, Cavallo F, Milone G, Ghiggi C, Pinto A, Pastore D, Ferreri AJM, Latte G, Patti C, Re F, Benedetti F, Luminari S, Pennese E, Bossi E, Boccomini C, Anastasia A, Bottelli C, Ciccone G, Vitolo U. Ladetto M, et al. Among authors: patti c. Ann Oncol. 2024 Jan;35(1):118-129. doi: 10.1016/j.annonc.2023.10.095. Epub 2023 Nov 3. Ann Oncol. 2024. PMID: 37922989 Free article. Clinical Trial.
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
Zinzani PL, Trněný M, Ribrag V, Zilioli VR, Walewski J, Christensen JH, Delwail V, Rodriguez G, Venugopal P, Coleman M, Dartigeas C, Patti C, Pane F, Jurczak W, Taszner M, Paneesha S, Zheng F, DeMarini DJ, Jiang W, Gilmartin A, Mehta A. Zinzani PL, et al. Among authors: patti c. EClinicalMedicine. 2023 Aug 10;62:102131. doi: 10.1016/j.eclinm.2023.102131. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37599908 Free PMC article.
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL.
Tisi MC, Moia R, Patti C, Evangelista A, Ferrero S, Spina M, Tani M, Botto B, Celli M, Puccini B, Cencini E, Di Rocco A, Chini C, Ghiggi C, Zambello R, Zanni M, Sciarra R, Bruna R, Ferrante M, Pileri SA, Quaglia FM, Stelitano C, Re A, Volpetti S, Zilioli VR, Arcari A, Merli F, Visco C. Tisi MC, et al. Among authors: patti c. Blood Adv. 2023 Aug 8;7(15):3916-3924. doi: 10.1182/bloodadvances.2023009744. Blood Adv. 2023. PMID: 37171620 Free PMC article.
147 results